Month: September 2022

New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells Encore presentation of data presented at Society for Investigative Dermatology in May 2022 shows:ALRN-6924 temporarily arrested the cell cycle in human scalp hair follicles and their stem cells Ex vivo data demonstrated protection against taxane-induced damage to hair follicles and their stem cellsNearly all breast cancer patients receiving neoadjuvant or adjuvant chemotherapy, including cyclophosphamide and taxanes, such as docetaxel, experience alopecia (hair loss) Aileron is evaluating ALRN-6924 as a novel chemoprotective agent to prevent chemotherapy-induced bone marrow toxicities and alopecia in its ongoing Phase 1b breast cancer trialBOSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics...

ŽEMAITIJOS PIENAS AB (hereinafter – the Company) delivers consolidated unaudited operating results of the Group for the 1st half of 2022:unaudited consolidated sales revenue of the Company group for the 1st half of  2022 amounts to EUR  122,7 million, in comparison with the 1st half of 2021 the sales revenue increased by 31,5 %; preliminary consolidated unaudited result of the Company group in terms of net profit for the 1st half of 2022 reached EUR 1,2 million.In accordance with Article 13 of the Law on Securities of the Republic of Lithuania, we also provide half-year information: (i) a set of consolidated financial statements for the first half of the financial year; (ii) a consolidated half-year report; and (iii) approval of the responsible persons. The person authorized to provide additional information: Arnas Matuzas Head of...

Artificial Intelligence Technology Solutions, Inc. Map of the United States showing the locations of the 10 schools that have been selected as recipients of RAD’s Bailey’s Gift ROSA with Firearm Detection systems.Detroit, Michigan, Sept. 30, 2022 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc., (OTCPK:AITX), today announced that its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD) has shipped the first of several ROSA security robots to a high school as part of the Bailey’s Gift campaign. Bailey’s Gift is named in memory of Bailey Holt, who was shot and killed by a gunman during the January 23, 2018, Marshall County High School shooting in rural Kentucky. Bailey’s mother, Secret Holt is an active advocate for better security in our school systems and is involved in the school selection and...

ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale in a registered direct offering of 9,660,000 shares of the Company’s common stock (or common stock equivalents), 33,810 shares of Series C mirroring preferred stock (“Series C Preferred”) and, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 9,660,000 shares of common stock, at a purchase price of $0.35 per share (or common stock equivalent). Each share of Series C Preferred Stock has a stated value of $0.01 per share and will...

MINNEAPOLIS, Sept. 30, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 20,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 30,150,000 shares of its common stock (the “Public Warrants”) at a purchase price of $0.30 per share and associated Public Warrant. The Public Warrants will have an exercise price of $0.30 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about October 4, 2022, subject to customary closing conditions. Roth Capital Partners, LLC is acting...

FORESIGHT ENTERPRISE VCT PLCLEI: 213800MWJNR3WZZ3ZP42 UNAUDITED HALF-YEARLY FINANCIAL REPORTFOR THE PERIOD ENDED 30 JUNE 2022 FINANCIAL HIGHLIGHTSTotal net assets £134.8 million An interim dividend of 3.5p per share was paid on 30 June 2022, returning £6.9 million to Shareholders The portfolio value has increased by £4.6 million in the last six months Net Asset Value per share decreased by 2.3% in the period from 69.1p at 31 December 2021 to 67.5p at 30 June 2022 Including the payment of a 3.5p dividend made on 30 June 2022, NAV Total Return per share at 30 June 2022 was 71.0p, representing a positive total return of 2.7% in the periodCHAIR’S STATEMENT I am pleased to present the unaudited Half-Yearly Report for Foresight Enterprise VCT plc for the period ended 30 June 2022. The business environment remains challenging after the substantial...

SINGAPORE, Sept. 30, 2022 (GLOBE NEWSWIRE) — ALR Technologies Inc. (“ALRT”) (OTCQB: ALRT), the diabetes management company, is pleased to announce an update with respect to its migration to Singapore. Further to its Form 8-K filed May 20, 2022, and press release issued May 20, 2022, the Registration Statement on Form F-4 filed by its affiliate, ALR Technologies SG Ltd. (“ALRT Singapore”), has been declared effective by the Securities and Exchange Commission (the “SEC”). ALRT anticipates mailing the corresponding prospectus and information statement to its stockholders on or around October 4, 2022. ALRT expects to consummate the previously announced reincorporation merger in which ALRT will become a wholly owned subsidiary of ALRT Singapore as soon as practicable following the required 20-day waiting period subsequent to mailing...

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that REVERSE, a Phase 3 study evaluating the safety and efficacy of OCA in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), did not meet its primary endpoint of a ≥ 1-stage histological improvement in fibrosis with no worsening of NASH following up to 18 months of therapy. No new safety signals for OCA were observed in this population of patients with cirrhosis. REVERSE...